Patient characteristics and predictors of sleep medication use

International Clinical Psychopharmacology

Volumn 25, Issue 2, 2010, Pages 91-100

  Omvik, Siri ^a   Pallesen, Ståle ^b,c   Bjorvatn, Bjørn ^a,c   Sivertsen, Børge ^a   Havik, Odd E ^a   Nordhus, Inger H ^a,c  

^a UNIVERSITY OF BERGEN   (Norway)

^b Psychosocial Science ^*

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Hypnotics; Sleep; Sleep disorders; Sleep medications

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; ZOLPIDEM; ZOPICLONE;

ADULT; AGE; AGED; ANXIETY DISORDER; ARTICLE; DEPRESSION; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NORWAY; PATIENT SATISFACTION; PERCEPTION; PREVALENCE; PRIORITY JOURNAL; SLEEP DISORDER; SOCIAL STATUS; SYMPTOM;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANXIETY; DEPRESSION; DRUG UTILIZATION; FEMALE; FORECASTING; HEALTH CARE SURVEYS; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; NORWAY; PATIENT SATISFACTION; QUESTIONNAIRES; SLEEP DISORDERS; SLEEP INITIATION AND MAINTENANCE DISORDERS; SUBSTANCE WITHDRAWAL SYNDROME; YOUNG ADULT;

EID: 76349090403     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e328334e5e6     Document Type: Article

References (56)

1. Ancoli-Israel S, Roth T (1999). Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. I. Sleep 22 (Suppl 2):347-353.
2. Anderson C, Horne JA (2008). Do we really want more sleep? A population-based study evaluating the strength of desire for more sleep. Sleep Med 9:184-187.
3. American Academy of Sleep Medicine (2005). Int classification of sleep disorders: diagnostic and coding manual. 2nd Edition. Westchester, IL: American Academy of Sleep Medicine.
4. American Psychiatric Association (2000). Diagnostic and statistical manual of mental disorders IV. Text revision. Washington, DC: American Psychiatric Association.
5. Asplund R (2000). Sleep and hypnotic use in relation to perceived somatic and mental health among the elderly. Arch Gerontol Geriatr 31:199-205.
6. Benca RM (2005). Diagnosis and treatment of chronic insomnia: a review. Psychiatr Servic 56:332-343.
7. Buscemi N, Vandermeer B, Friesen C, Bialy L, Tubman M, Ospina M, et al. (2007). The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. J Gen Intern Med 22:1335-1350.
8. Dixon S, Morgan K, Mathers N, Thompson J, Tomeny M (2006). Impact of cognitive behavior therapy on health-related quality of life among adult hypnotic users with chronic insomnia. Behav Sleep Med 4:71-84.
9. Edwards P, Roberts I, Clarke M, Diguiseppi C, Pratap S, Wentz R, et al. (2007). Methods to increase response rates to postal questionnaires. Cochrane Database Syst Rev 18:MR000008.
10. First MB, Spitzer RL, Gibbon M, Williams JBW (1995). Structural clinical interview for DSM-IV axis I disorders. New York: Biometrics Research Department.
11. Ford DE, Kamerow DB (1989). Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA 262:1479-1484.
12. Glass J, Lanctôt KL, Herrmann N, Sproule BA, Busto UE (2005). Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. Br Med J 331:1169-1173.
13. Goodwin RD, Hasin DS (2002). Sedative use and misuse in the United States. Addiction 97:555-562.
14. Gossop M, Darke S, Griffiths P, Hando J, Powis B, Hall W, et al. (1995). The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 90:607-614.
15. Guilleminault C (1990). Benzodiazepines, breathing, and sleep. Am J Med 88:25-28.
16. Hajak G (1999). A comparative assessment of the risks and benefits of zopiclone: a review of 15 years' clinical experience. Drug Saf 21:457-469.
17. Harper A, Power M (1998). Development of the World Health Organization WHOQOL-BREF quality of life assessment. The WHOQOL Group. Psychol Med 28:551-558.
18. Hauri PJ (1997). Can we mix behavioral therapy with hypnotics when treating insomniacs? Sleep 20:1111-1118.
19. Hausken AM, Furu K, Skurtveit S, Engeland A, Bramness JG (2009). Starting insomnia treatment: the use of benzodiazepines versus z-hypnotics. A prescription database study of predictors. Eur J Clin Pharmacol 65:295-301.
20. Hoedemaekers E, Jaspers JPC, Van Tintelen JP (2007). The influence of coping styles and perceived control on emotional distress in persons at risk for a hereditary heart disease. Am J Med Genet A 143:1997-2005.
21. Hohagen F, Kappler C, Schramm E, Rink K, Weyerer S, Riemann D, et al. (1994). Prevalence of insomnia in elderly general practice attenders and the current treatment modalities. Acta Psychiatr Scand 90:102-108.
22. Holm KJ, Goa KL (2000). Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 59:865-889.
23. Husby R, Lingjaerde O (1990). Prevalence of reported sleeplessness in northern Norway in relation to sex, age and season. Acta Psychiatr Scand 81:542-547.
24. Jansson M, Linton SJ (2006). The role of anxiety and depression in the development of insomnia: cross-sectional and prospective analyses. Psychol Health 21:383-397.
25. Johnson EO, Roth T, Breslau NHH (2006). The association of insomnia with anxiety disorders and depression: exploration of the direction of risk. J Psychiatr Res 40:700-708.
26. Kaneita Y, Uchiyama M, Takemura S, Yokoyama E, Miyake T, Harano S, et al. (2007). Use of alcohol and hypnotic medication as aids to sleep among the Japanese general population. Sleep Med 8:723-732.
27. Kassam A, Patten SB (2006). Hypnotic use in a population-based sample of over thirty-five thousand interviewed Canadians. Popul Health Metr 4:15.
28. Krystal AD (2009). A compendium of placebo-controlled trials of the risks/ benefits of pharmacological treatments for insomnia: the empirical basis for US clinical practice. Sleep Med Rev 13:265-274.
29. Krystal AD, Walsh JK, Laska E, Caron J, Amato DA, Wessel TC, Roth T (2003). Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 26:793-799.
30. Krystal AD, Erman M, Zammit GK, Soubrane C, Roth T (2008). Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep 31:79-90.
31. Lu B, Budhiraja R, Parthasarathy S (2005). Sedating medications and undiagnosed obstructive sleep apnea: physician determinants and patient consequences. J Clin Sleep Med 15:367-371.
32. McLaren S, Crowe SF (2003). The contribution of perceived control of stressful life events and thought suppression to the symptoms of obsessive-compulsive disorder in both non-clinical and clinical samples. J Anxiety Disord 17:389-403.
33. Morin CM, Colecchi C, Stone J, Sood R, Brink D (1999). Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA 281:991-999.
34. Morin CM, Wooten V (1996). Psychological and pharmacological approaches to treating insomnia: critical issues in assessing their separate and combined effects. Clin Psychol Rev 16:521-542.
35. National Institutes of Health (2005). National Institutes of Health state of the science conference statement on manifestations and management of chronic insomnia in adults, June 13-15, 2005. Sleep 28:1049-1057.
36. Noble S, Langtry HD, Lamb HM (1998). Zopiclone. An update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia. Drugs 55:277-302.
37. Nowell PD, Mazumdar S, Buysse DJ, Dew MA, Reynolds CF III, Kupfer DJ (1997). Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA 278:2170-2177.
38. Ohayon MM (1996). Epidemiological study on insomnia in the general population. Sleep 19:7-15.
39. Ohayon MM (2002). Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 6:97-111.
40. Pallesen S, Nordhus IH, Nielsen GH, Havik OE, Kvale G, Johnsen BH, et al. (2001). Prevalence of insomnia in the adult Norwegian population. Sleep 24:771-779.
41. Pallesen S, Bjorvatn B, Nordhus IH, Sivertsen B, Hjørnevik M, Morin CM (2008). A new scale for measuring insomnia: the Bergen Insomnia Scale. Percept Mot Skills 107:691-706.
42. Quera-Salva MA, Orluc A, Goldenberg F, Guilleminault C (1991). Insomnia and use of hypnotics: study of a French population. Sleep 14:386-391.
43. Roth T, Zammit GK, Kushida C, Doghramji K, Mathias SD, Wong JM, et al. (2002). A new questionnaire to detect sleep disorders. Sleep Med 3:99-108.
44. Schubert CR, Cruickshanks KJ, Dalton DS, Klein BE, Klein R, Nondahl DM (2002). Prevalence of sleep problems and quality of life in an older population. Sleep 25:889-893.
45. Sivertsen B, Omvik S, Pallesen S, Bjorvatn B, Havik OE, Kvale G, et al. (2006). Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial. JAMA 295:2851-2858.
46. Smith MT, Perlis ML, Park A, Smith MS, Pennington J, Giles DE, et al. (2002). Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry 159:5-11.
47. Souza JC, Magna LA, Reimão R (2002). Insomnia and hypnotic use in Campo Grande general population, Brazil. Arq Neuropsiquiatr 60:702-707.
48. Stein MB, Barrett-Connor E (2002). Quality of life in older adults receiving medications for anxiety, depression, or insomnia: findings from a community-based study. Am J Geriatr Psychiatry 10:568-574.
49. Storms MD, Nisbett RE (1970). Insomnia and the attribution process. J Pers Soc Psychol 16:319-328.
50. Tan G, Jensen MP, Robinson-Whelen S, Thornby JI, Monga T (2002). Measuring control appraisals in chronic pain. J Pain 3:385-393.
51. Ursin R, Bjorvatn B, Holsten F (2005). Sleep duration, subjective sleep need, and sleep habits of 40-to 45-year-olds in the Hordaland health study. Sleep 28:1260-1269.
52. Vermeeren A (2004). Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs 18:297-328.
53. Vincent N, Lionberg C (2001). Treatment preference and patient satisfaction in chronic insomnia. Sleep 24:411-417.
54. Walsh JK, Krystal AD, Amato DA, Rubens R, Caron J, Wessel TC, et al. (2007). Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep 30:959-968.
55. Wardle J, Steptoe A, Gulis G, Sartory G, Sêk H, Todorova I, et al. (2004). Depression, perceived control, and life satisfaction in university students from Central-Eastern and Western Europe. Int J Behav Med 11:27-36.
56. World Health Organization (1992). The ICD-10 classification of mental and behavioural disorders, clinical description and diagnostic guidelines. Geneva: World Health Organization.